Heeringa P - Search Results

1

Urinary Soluble CD163 and Disease Activity in Biopsy-Proven ANCA-Associated Glomerulonephritis.

Aendekerk JP, Timmermans SAMEG, Busch MH, Potjewijd J, Heeringa P, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P; Limburg Renal Registry. Aendekerk JP, et al. Among authors: heeringa p. Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1740-1748. doi: 10.2215/CJN.07210520. Epub 2020 Nov 17. Clin J Am Soc Nephrol. 2020. PMID: 33203735 Free PMC article.

2

ANCA and anti-GBM antibodies in diagnosis and follow-up of vasculitic disease.

Rutgers A, Heeringa P, Damoiseaux JG, Tervaert JW. Rutgers A, et al. Among authors: heeringa p. Eur J Intern Med. 2003 Aug;14(5):287-295. doi: 10.1016/s0953-6205(03)00097-9. Eur J Intern Med. 2003. PMID: 13678753

3

Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis.

Rutgers A, Slot M, van Paassen P, van Breda Vriesman P, Heeringa P, Tervaert JW. Rutgers A, et al. Among authors: heeringa p. Am J Kidney Dis. 2005 Aug;46(2):253-62. doi: 10.1053/j.ajkd.2005.05.003. Am J Kidney Dis. 2005. PMID: 16112043 Review.

4

Mechanisms of vasculitis: how pauci-immune is ANCA-associated renal vasculitis?

van Paassen P, Tervaert JW, Heeringa P. van Paassen P, et al. Among authors: heeringa p. Nephron Exp Nephrol. 2007;105(1):e10-6. doi: 10.1159/000096960. Nephron Exp Nephrol. 2007. PMID: 17108705 Free article. Review.

5

TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations.

Huugen D, Tervaert JW, Heeringa P. Huugen D, et al. Among authors: heeringa p. Clin J Am Soc Nephrol. 2006 Sep;1(5):1100-7. doi: 10.2215/CJN.02181205. Epub 2006 Aug 2. Clin J Am Soc Nephrol. 2006. PMID: 17699331 Review.

6

Anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOE and APOECD40L mice.

Smook ML, van Leeuwen M, Heeringa P, Damoiseaux JG, Theunissen R, Daemen MJ, Lutgens E, Tervaert JW. Smook ML, et al. Among authors: heeringa p. Clin Exp Immunol. 2008 Nov;154(2):264-9. doi: 10.1111/j.1365-2249.2008.03746.x. Epub 2008 Sep 5. Clin Exp Immunol. 2008. PMID: 18778362 Free PMC article.

7

The IgM response to modified LDL in experimental atherosclerosis: hypochlorite-modified LDL IgM antibodies versus classical natural T15 IgM antibodies.

van Leeuwen M, Damoiseaux J, Duijvestijn A, Heeringa P, Gijbels M, de Winther M, Tervaert JW. van Leeuwen M, et al. Among authors: heeringa p. Ann N Y Acad Sci. 2009 Sep;1173:274-9. doi: 10.1111/j.1749-6632.2009.04657.x. Ann N Y Acad Sci. 2009. PMID: 19758162

8

IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis.

van Timmeren MM, van der Veen BS, Stegeman CA, Petersen AH, Hellmark T, Collin M, Heeringa P. van Timmeren MM, et al. Among authors: heeringa p. J Am Soc Nephrol. 2010 Jul;21(7):1103-14. doi: 10.1681/ASN.2009090984. Epub 2010 May 6. J Am Soc Nephrol. 2010. PMID: 20448018 Free PMC article.

9

Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission.

Tadema H, Abdulahad WH, Lepse N, Stegeman CA, Kallenberg CG, Heeringa P. Tadema H, et al. Among authors: heeringa p. Rheumatology (Oxford). 2011 Apr;50(4):689-96. doi: 10.1093/rheumatology/keq375. Epub 2010 Dec 11. Rheumatology (Oxford). 2011. PMID: 21149241

10

Reactivity against complementary proteinase-3 is not increased in patients with PR3-ANCA-associated vasculitis.

Tadema H, Kallenberg CG, Stegeman CA, Heeringa P. Tadema H, et al. Among authors: heeringa p. PLoS One. 2011 Mar 17;6(3):e17972. doi: 10.1371/journal.pone.0017972. PLoS One. 2011. PMID: 21437233 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

202 results

Search Page